RxDoctor Payments Data

Brandon Jahnke, MD

General Practice · Sutton, NENPI 1790893931

Payments from drug & device makers

$479in general payments, 2019–2025

Across 24 payments — averaging $19.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$114
  • Novo Nordisk$59
  • Gilead$54
  • Lilly USA, LLC$39
  • Otsuka America Pharmaceutical, Inc.$39
  • Amgen$32
  • plus $142 from 8 others

What the payments were for

  • Food & beverage$479100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$479 in reported general payments places this provider in the 65th percentile of 541 general practice providers in Nebraska.

See all general practice providers in Nebraska

Medicare billing

Part B allowed, 2024
$33,203
Medicare patients
121
Services billed
740

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin60$53,771
TrulicityDulaglutide45$51,471
OzempicSemaglutide30$32,568
JanuviaSitagliptin Phosphate20$31,871
RybelsusSemaglutide15$22,168
FarxigaDapagliflozin Propanediol20$16,819
MounjaroTirzepatide14$15,053
EntrestoSacubitril/Valsartan18$11,980
Breztri AerosphereBudesonide/Glycopyr/Formoterol12$7,841
BaqsimiGlucagon13$7,668
Insulin Lispro Kwikpen U-100Insulin Lispro22$5,835
Lantus SolostarInsulin Glargine,hum.Rec.Anlog37$4,979
Omega-3 Acid Ethyl Esters24$2,973
Levemir FlexpenInsulin Detemir11$2,944
Ultra-Fine Short Pen NeedlePen Needle, Diabetic22$1,527

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro, Baqsimi$39$74,19172 claims
Novo NordiskOzempic, Rybelsus$59$54,73645 claims
AstraZenecaFarxiga, Breztri Aerosphere$114$24,66032 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 541 general practice providers in Nebraska.

Other general practice in Sutton

See the full list for Nebraska

Where these figures come from

Is this you, or does something look wrong? →